Results 11 to 20 of about 10,846 (218)

BV/ODV-E26 is a conserved baculoviral inhibitory factor for optimizing viral virulence in lepidopteran hosts [PDF]

open access: yesiScience
Summary: Alphabaculoviruses induce abnormal behavior in lepidopteran larval hosts. A baculoviral gene, bv/odv-e26, is crucial for behavioral manipulation in Bombyx mori larvae by Bombyx mori nucleopolyhedrovirus (BmNPV).
Hiroyuki Hikida   +2 more
doaj   +7 more sources

Magnetic Signatures of a Plume at Europa During the Galileo E26 Flyby [PDF]

open access: yesGeophysical Research Letters, 2019
We analyze the magnetic field perturbations observed near Jupiter's icy moon Europa by the Galileo spacecraft during the E26 flyby on 3 January 2000. In addition to the expected large‐scale signatures of magnetic fieldline draping and induction, the E26 ...
Hannes Arnold, Lucas Liuzzo, Sven Simon
doaj   +3 more sources

BV/ODV-E26: A palmitoylated, multifunctional structural protein of Autographa californica nucleopolyhedrovirus [PDF]

open access: yesVirology, 2007
Autographa californica nucleopolyhedrovirus Ac16 is 1 of 17 genes conserved within Type 1 nucleopolyhedroviruses. This report demonstrates that multiple isoforms of the protein encoded by Ac16, BV/ODV-E26 (E26), are present in the infected cell. One form of E26 associates with viral DNA or DNA-binding proteins, while a second form associates with ...
Max D Summers, Sharon C Braunagel
exaly   +4 more sources

Comment on “An Active Plume Eruption on Europa During Galileo Flyby E26 as Indicated by Energetic Proton Depletions” by Huybrighs et al. [PDF]

open access: yesGeophysical Research Letters, 2021
The Galileo spacecraft passed close to Europa on 11 encounters, two of which (E12 and E26) came within 400 km of the surface. In E12 data, there are perturbations in field and plasma data consistent with effects of a nearby plume (Jia et al., 2018 ...
Xianzhe Jia   +2 more
doaj   +2 more sources

Myeloblasts transformed by the avian acute leukemia virus E26 are hormone-dependent for growth and for the expression of a putative myb-containing protein, p135 E26. [PDF]

open access: yesEMBO Journal, 1982
Avian leukemia virus E26 contains the myb oncogene and transforms erythroid and myeloid hematopoietic cells in vivo and in vitro. E26-transformed nonproducer myeloblasts but not avian erythroleukemia virus (AEV)-transformed erythroblasts nor MC29-transformed macrophages were shown to be dependent for growth on factor(s) present in supernatants from ...
Thomas Graf, H Beug
exaly   +3 more sources

ERG (v-ets erythroblastosis virus E26 oncogene like (avian)) [PDF]

open access: yesAtlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on ERG (v-ets erythroblastosis virus E26 oncogene like (avian)), with data on DNA, on the protein encoded, and where the gene is implicated.
S Izraeli, L Rainis-Ganon
openaire   +3 more sources

Uncovering the ecophysiological potential of Motilimonas through genomic profiling analysis [PDF]

open access: yesBMC Genomics
Background The Motilimonas genus was proposed in 2017 and presently include three recognized species isolated from various environments. This genus is still poorly characterized, and its ability to degrade chitin has recently been reported.
Arthur Salengros   +3 more
doaj   +2 more sources

Characterization of the hemopoietic target cells for the avian leukemia virus E26

open access: yesVirology, 1983
The dual leukemogenic response, involving both the erythroid and myeloid hemopoietic systems in chickens infected with E26 virus, has previously been described (C. Moscovici, J. Samarut, L. Gazzolo, and M. G. Moscovici, 1981. Virology 113, 765-768; K. Radke, H. Beug, S. Kornfeld, and T. Graf, 1982. Cell 31, 643-653). Similarly, the in vitro response of
Casilda V Mura, P Jurdic, C Moscovici
exaly   +4 more sources

Reply to “Infliximab therapy in hematologic malignancies: handle with care” 2012;97(8):e26

open access: yesHaematologica, 2012
We are grateful for the comments of Stagno et al .[1][1] on potential toxicities of infliximab in patients with hematologic malignancies. We agree that the occurrence of secondary malignancies could be a potential concern for infliximab use in patients with low-risk MDS, although none of the ...
Frédéric Baron, Theo de Witte
doaj   +3 more sources

Home - About - Disclaimer - Privacy